Ribosomal S6 Kinase and AKT Phosphorylation as Pharmacodynamic Biomarkers in Patients With Myelodysplastic Syndrome Treated With RAD001

The pS6:pAKT ratio could be useful as a biomarker of target inhibition by RAD001 (clinicaltrials.gov identifier: NCT00809185).